Katlama C - Search Results

1

Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).

Joly V, Burdet C, Landman R, Vigan M, Charpentier C, Katlama C, Cabié A, Benalycherif A, Peytavin G, Yeni P, Mentre F, Argoud AL, Amri I, Descamps D, Yazdanpanah Y; LAMIDOL Study Group. Joly V, et al. Among authors: katlama c. J Antimicrob Chemother. 2019 Mar 1;74(3):739-745. doi: 10.1093/jac/dky467. J Antimicrob Chemother. 2019. PMID: 30476165 Clinical Trial.

2

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, Johnson M, Hill AM, Pearce G, McDade H. Katlama C, et al. JAMA. 1996 Jul 10;276(2):118-25. JAMA. 1996. PMID: 8656503 Clinical Trial.

3

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, Herson S, Poynard T, Opolon P. Benhamou Y, et al. Among authors: katlama c. Ann Intern Med. 1996 Nov 1;125(9):705-12. doi: 10.7326/0003-4819-125-9-199611010-00001. Ann Intern Med. 1996. PMID: 8929003

4

Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysis.

Descamps D, Calvez V, Collin G, Cécille A, Apetrei C, Damond F, Katlama C, Matheron S, Huraux JM, Brun-Vézinet F. Descamps D, et al. Among authors: katlama c. J Clin Microbiol. 1998 Jul;36(7):2143-5. doi: 10.1128/JCM.36.7.2143-2145.1998. J Clin Microbiol. 1998. PMID: 9650987 Free PMC article. Clinical Trial.

5

Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection.

Katlama C, Valantin MA, Matheron S, Coutellier A, Calvez V, Descamps D, Longuet C, Bonmarchand M, Tubiana R, De Sa M, Lancar R, Agut H, Brun-Vezinet F, Costagliola D. Katlama C, et al. Ann Intern Med. 1998 Oct 1;129(7):525-31. doi: 10.7326/0003-4819-129-7-199810010-00003. Ann Intern Med. 1998. PMID: 9758571

6

A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.

Staszewski S, Katlama C, Harrer T, Massip P, Yeni P, Cutrell A, Tortell SM, Harrigan RP, Steel H, Lanier RE, Pearce G. Staszewski S, et al. Among authors: katlama c. AIDS. 1998 Nov 12;12(16):F197-202. doi: 10.1097/00002030-199816000-00001. AIDS. 1998. PMID: 9833847 Clinical Trial.

7

Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance.

Mouroux M, Yvon-Groussin A, Peytavin G, Delaugerre C, Legrand M, Bossi P, Do B, Trylesinski A, Diquet B, Dohin E, Delfraissy JF, Katlama C, Calvez V. Mouroux M, et al. Among authors: katlama c. J Clin Microbiol. 2000 Jul;38(7):2726-30. doi: 10.1128/JCM.38.7.2726-2730.2000. J Clin Microbiol. 2000. PMID: 10878071 Free PMC article. Clinical Trial.

8

[Conditions of "thymidine analog mutations" (TAMs) in naive patients treated with different combinations of d4T].

Mouroux M, Izopet J, Descamps D, Delaugerre C, Yvon-Groussin A, Angleraud F, Coutellier A, Bonmarchand M, Valantin MA, Matheron S, Agut H, Katlama C, Brun-Vezinet F, Calvez V. Mouroux M, et al. Among authors: katlama c. Pathol Biol (Paris). 2000 Jun;48(5):508-12. Pathol Biol (Paris). 2000. PMID: 10949850 French.

9

Prevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practice.

Delaugerre C, Mouroux M, Yvon-Groussin A, Simon A, Angleraud F, Huraux JM, Agut H, Katlama C, Calvez V. Delaugerre C, et al. Among authors: katlama c. Antimicrob Agents Chemother. 2001 Mar;45(3):946-8. doi: 10.1128/AAC.45.3.946-948.2001. Antimicrob Agents Chemother. 2001. PMID: 11181387 Free PMC article.

10

Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy.

Jouan M, Savès M, Tubiana R, Carcelain G, Cassoux N, Aubron-Olivier C, Fillet AM, Nciri M, Sénéchal B, Chêne G, Tural C, Lasry S, Autran B, Katlama C; RESTIMOP study team. Jouan M, et al. Among authors: katlama c. AIDS. 2001 Jan 5;15(1):23-31. doi: 10.1097/00002030-200101050-00006. AIDS. 2001. PMID: 11192865 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

944 results

Search Page

Filters